Affinity Asset Advisors LLC Has $17.97 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Affinity Asset Advisors LLC reduced its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 425,000 shares of the company’s stock after selling 10,000 shares during the period. Vera Therapeutics accounts for approximately 2.4% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 13th biggest position. Affinity Asset Advisors LLC owned approximately 0.67% of Vera Therapeutics worth $17,973,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC raised its stake in Vera Therapeutics by 116.7% in the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock worth $857,000 after purchasing an additional 10,916 shares in the last quarter. Lord Abbett & CO. LLC increased its holdings in Vera Therapeutics by 41.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after buying an additional 124,197 shares during the period. Barclays PLC raised its position in shares of Vera Therapeutics by 94.1% in the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after buying an additional 41,394 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Vera Therapeutics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after acquiring an additional 20,223 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Vera Therapeutics in the fourth quarter valued at approximately $2,948,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on VERA. Wolfe Research started coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price target for the company. JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. Guggenheim lifted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group started coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Price Performance

VERA opened at $21.50 on Tuesday. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.24 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $27.25 and a 200-day moving average price of $37.06. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.